Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on July 25, 2017, to report the completion of a private placement and a debt exchange transaction. The company is a Delaware corporation with principal executive offices in Carmiel, Israel.
Key Financial Metrics and Transactions
- Private Placement: Issued $10 million aggregate principal amount of 7.50% Senior Secured Convertible Notes due 2021.
- Debt Exchange: Exchanged $9 million of existing 4.50% Convertible Senior Notes due 2018 for:
- $8.55 million of new 4.50% Senior Convertible Notes due 2022.
- $275,000 in cash consideration.
- $146,250 in cash for accrued and unpaid interest.
- Interest Terms:
- 7.50% Notes: 7.50% per annum, paid semi-annually; company may elect to pay up to 1.25% in common stock.
- 4.50% Notes: 4.50% per annum, paid semi-annually.
- Liquidity and Cash Flow: The filing does not provide specific cash balance, operating cash flow, or liquidity metrics. The transaction involved cash outflows of approximately $421,250 for the exchange consideration and accrued interest.
Material Changes Versus Prior Period
This filing represents a discrete event rather than a periodic financial report. The material change is the restructuring of the company's debt profile:
- Extension of maturity dates for a portion of existing debt from 2018 to 2022.
- Introduction of new senior secured debt with a higher interest rate (7.50%) maturing in 2021.
- Reduction of total principal debt outstanding by $450,000 ($9 million old notes exchanged for $8.55 million new notes).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operations. Key risks and contingencies identified include:
- Unregistered Securities: Neither the new notes nor shares issuable upon conversion are registered under the Securities Act.
- Debt Obligations: The company has created direct financial obligations with semi-annual interest payments and specific maturity dates (2021 and 2022).
- Collateral: The 7.50% Notes are secured and guaranteed by the company's subsidiaries.
Investor Verification Checklist
- Verify the full text of the Note Purchase Agreement (Exhibit 10.1) and Exchange Agreement (Exhibit 10.2) for covenants and default provisions.
- Confirm the impact of the new debt on the company's leverage ratios and ability to service debt given the 7.50% interest rate.
- Review the press release (Exhibit 99.1) for any additional context on the use of proceeds from the $10 million private placement.
- Assess the dilution risk associated with the convertible features of both the 7.50% and 4.50% notes.